Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.
Swiss Noema Pharma raises CHF54m in Series A financing
Latest NewsNoema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG.
Germany first EU country to launch COVID-19 therapy offensive?
Latest NewsAfter months of lobbying by the BIOM biotech cluster, Bavaria is launching a €50m initiative to push the best and fastest COVID-19 therapies.
Moderna to file for EU approval of mRNA-1273 vaccine
Latest NewsCOVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
Latest NewsAviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Rapid antibody development to cure COVID-19
Latest NewsIn addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options for patients infected and suffering from Covid-19 disease. Virus-neutralising antibody therapeutics can not only cure COVID-19 but also protect from infection. New fast-track antibody drug programmes have achieved unprecedented timelines from discovery to the clinics and give hope to save lives and cure COVID-19.
New at Polyplus-transfection
AppointmentsFrench Polyplus-transfection SA named Mario Philips as new CEO. He succeeds Karsten Wilking, now a Strategic Advisor of the biotech company, specialist for innovative transfection solutions to support the gene and cell therapy market.
Polyphor AG bags funding for murepavadin
Latest NewsPolyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
Women’s health from niche to mainstream
OpinionWomen make up half of the world’s population. Finally, pharma companies and invetors are now beginning to pay more attention to female diseases.
Startup Labs at the Vienna BioCenter
Sponsored PublicationsThe Vienna Business Agency has set up affordable and flexible Startup Labs at the Vienna BioCenter. This will speed up the evaluation and implementation of new business ideas in biotechnology by the next coming generation of bio-entrepreneurs. Key assets include close proximity to outstanding academic research and highly successful innovators as well as access to cutting-edge research infrastructure.
Searching for an effective treatment for COVID-19
Latest NewsApogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.